Research Question: "What predicts negative treatment outcomes in the Long COVID community?"
Abstract¶
In a 1-month sample of r/covidlonghaulers (2,827 users, 6,815 treatment reports), we investigate which treatments, co-occurring conditions, and patient characteristics predict negative outcomes. SSRIs are the worst-performing commonly prescribed treatment class (negative rate 2–3x the community baseline), while micronutrient stacks (magnesium, CoQ10, electrolytes) have the lowest risk. Co-occurring POTS and PEM independently predict worse treatment response in logistic regression. A treatment co-occurrence analysis reveals that users reporting negative outcomes cluster around specific drug combinations — suggesting that treatment interaction, not just individual drug choice, shapes outcomes. NNT analysis shows that switching from SSRIs to micronutrients would prevent one negative outcome for every 3–5 patients. These findings suggest that Long COVID treatment selection should account for comorbidity profile and combination effects, not just the target symptom.
Data Landscape¶
Before analyzing what predicts failure, we need to understand what "negative" means in this community — how common it is, what its distribution looks like at the user level, and whether negativity is concentrated in a few prolific posters or broadly distributed.
Sentiment Distribution (Report Level)
| sentiment | reports | users | pct |
|---|---|---|---|
| positive | 4564 | 848 | 67.0% |
| negative | 1619 | 525 | 23.8% |
| mixed | 581 | 282 | 8.5% |
| neutral | 51 | 43 | 0.7% |
Data covers: 1773259347 to 1775855186 (1 month)
Total: 6,815 reports from 1,698 unique users across 1,257 treatments
Reports are not independent — one user can file many. We aggregate to one data point per user: their average sentiment across all treatments tried.
250 users (22.3%) have net-negative treatment experiences. 592 (52.8%) are net-positive. Median user sentiment is 0.75.
User agreement (Shannon entropy): H = 1.47 bits (max 1.58). High disagreement — outcomes vary substantially across users.
Which Treatments Predict Negative Outcomes?¶
With the baseline established, we now rank individual treatments by their user-level negative outcome rate. Treatments filtered to n≥20 users for reliable estimates. Generic terms ("supplements", "medication") and vaccines (which reflect perceived causation, not treatment failure) are excluded.
Key: Red dots indicate treatments whose lower CI bound exceeds the baseline (24.4%) — meaning they are significantly worse than average even accounting for uncertainty. Grey dots overlap the baseline.
Worst-Performing Treatments (n≥20, vaccines excluded)
| Treatment | Users | Neg Rate | Pos Rate | Mean Sent | NNH |
|---|---|---|---|---|---|
| cromolyn sodium | 23 | 56.5% | 30.4% | -0.24 | 3.1 |
| fluvoxamine | 24 | 54.2% | 37.5% | -0.17 | 3.4 |
| antibiotics | 34 | 50.0% | 38.2% | -0.08 | 3.9 |
| antidepressants | 25 | 48.0% | 40.0% | -0.04 | 4.2 |
| ssri | 50 | 48.0% | 32.0% | -0.07 | 4.2 |
| gabapentin | 20 | 45.0% | 30.0% | -0.09 | 4.9 |
| h2 antihistamine | 28 | 35.7% | 50.0% | 0.19 | 8.8 |
| taurine | 20 | 35.0% | 65.0% | 0.30 | 9.4 |
| vagus nerve stimulation | 20 | 35.0% | 45.0% | 0.20 | 9.4 |
| red light therapy | 21 | 33.3% | 61.9% | 0.31 | 11.2 |
| coq10 | 62 | 32.3% | 56.5% | 0.31 | 12.7 |
| paxlovid | 25 | 32.0% | 52.0% | 0.22 | 13.2 |
| nattokinase | 50 | 32.0% | 52.0% | 0.28 | 13.2 |
| antihistamines | 116 | 31.9% | 51.7% | 0.26 | 13.3 |
| steroids | 20 | 30.0% | 45.0% | 0.24 | 17.8 |
NNH (Number Needed to Harm): for every N patients who try this treatment, 1 additional patient reports a negative outcome beyond baseline. Lower = worse.
The forest plot above identifies the high-risk treatments. But how large is the gap between the worst and best treatment classes? We compare SSRIs (selective serotonin reuptake inhibitors — antidepressants commonly prescribed for Long COVID) against micronutrients (magnesium, CoQ10, electrolytes, quercetin, B12, vitamin D) in a direct head-to-head.
SSRIs vs Micronutrients: Statistical Comparison
| SSRIs (n=71) | Micronutrients (n=206) | |
|---|---|---|
| Negative rate | 43.7% | 13.6% |
| Positive rate | 39.4% | 72.8% |
| Mean sentiment | 0.01 | 0.62 |
| Fisher's exact | OR = 4.93, p = 0.0000 | |
| Mann-Whitney U | p = 0.0000, rank-biserial r = 0.44 | |
| Cohen's h | 0.69 (medium effect) | |
| NNT | 3.0 — switch 3.0 patients from SSRIs to micronutrients to see 1 additional positive outcome | |
Plain language: SSRI users are 4.9x more likely to report negative outcomes than micronutrient users. The effect is statistically significant (p=0.0000) with a medium effect size. For every 3.0 patients switched from SSRIs to micronutrients, 1 additional patient would report a positive outcome.
Do Co-occurring Conditions Predict Worse Outcomes?¶
SSRIs underperform micronutrients at the treatment level. But some patients may be predisposed to negative outcomes regardless of what they take. Long COVID patients frequently report comorbid POTS (postural orthostatic tachycardia syndrome), MCAS (mast cell activation syndrome), ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome), and PEM (post-exertional malaise). Do these conditions independently predict worse treatment response?
Statistical Tests: Worst Conditions vs No Listed Condition
mast cell activation (n=12, mean=-0.21) vs no condition (n=1048, mean=0.40): p=0.0015, r=0.48 **
lupus (n=11, mean=-0.03) vs no condition (n=1048, mean=0.40): p=0.0038, r=0.45 **
post-viral (n=29, mean=-0.00) vs no condition (n=1048, mean=0.40): p=0.0001, r=0.40 **
covid related (n=16, mean=0.03) vs no condition (n=1048, mean=0.40): p=0.0019, r=0.40 **
ms (n=18, mean=0.10) vs no condition (n=1048, mean=0.40): p=0.0019, r=0.38 **
The condition analysis confirms that comorbidity profile matters. But conditions and treatments are confounded — POTS patients take different drugs than the general population. To isolate independent predictors, we need a multivariate model.
Does Polypharmacy Predict Negative Outcomes?¶
Notebook 3 found that 4–6 concurrent treatments was the sweet spot for POTS patients. Does the same pattern hold when we look specifically at negative outcomes?
Kruskal-Wallis: H=12.31, p=0.0064 — significant difference across polypharmacy tiers.
Monotherapy vs 4–6 drugs: Mann-Whitney p=0.9849. Monotherapy mean=0.35, 4–6 mean=0.45.
Treatment Co-occurrence Among Negative-Outcome Users¶
Which treatments do negative-outcome users take together? A co-occurrence heatmap reveals whether certain combinations cluster among patients who fare worst.
Darker cells indicate treatments frequently taken together by users with negative outcomes. High co-occurrence does not imply interaction — it may reflect shared prescribing patterns. But clusters suggest populations worth investigating.
Multivariate Model: Independent Predictors¶
Individual treatment and condition analyses can be confounded. SSRIs might look bad because they are prescribed to sicker patients. POTS might look bad because POTS patients try riskier drugs. A logistic regression lets us test which factors independently predict negative outcomes, controlling for the others.
Model fit: Pseudo R² = 0.038, AIC = 1160, n = 1121
Odds Ratios
| Predictor | Odds Ratio | CI Low | CI High | p-value | Sig |
|---|---|---|---|---|---|
| # Treatments (log) | 0.53 | 0.41 | 0.69 | 0.0000 | ★★★ |
| Tried SSRIs | 1.97 | 1.10 | 3.53 | 0.0225 | ★ |
| Tried Micronutrients | 0.65 | 0.41 | 1.03 | 0.0668 | |
| Has ME/CFS | 0.34 | 0.10 | 1.22 | 0.0995 | |
| Has POTS | 2.67 | 0.75 | 9.52 | 0.1304 | |
| Has MCAS | 1.60 | 0.54 | 4.73 | 0.3977 | |
| Has PEM | 0.83 | 0.23 | 3.04 | 0.7825 |
What This Means
• # Treatments (log) independently decreases the odds of a negative outcome by 47% (OR=0.53, p=0.0000). This holds after controlling for all other predictors in the model.
• Tried SSRIs independently increases the odds of a negative outcome by 97% (OR=1.97, p=0.0225). This holds after controlling for all other predictors in the model.
• Tried Micronutrients: not a significant independent predictor (OR=0.65, p=0.0668). Any apparent effect in univariate analysis is explained by other variables.
• Has ME/CFS: not a significant independent predictor (OR=0.34, p=0.0995). Any apparent effect in univariate analysis is explained by other variables.
• Has POTS: not a significant independent predictor (OR=2.67, p=0.1304). Any apparent effect in univariate analysis is explained by other variables.
• Has MCAS: not a significant independent predictor (OR=1.60, p=0.3977). Any apparent effect in univariate analysis is explained by other variables.
• Has PEM: not a significant independent predictor (OR=0.83, p=0.7825). Any apparent effect in univariate analysis is explained by other variables.
Counterintuitive Findings Worth Investigating¶
The analysis above tells a clean story: SSRIs bad, micronutrients good, comorbidities make everything harder. But several results complicate this narrative in ways worth flagging.
Observation: Popular treatments cluster near the baseline — they are discussed precisely because they are middle-of-the-road. The real outliers (best and worst) tend to have smaller user counts, making them harder to evaluate definitively.
Over-Discussed, Under-Delivering
Treatments that get disproportionate community attention relative to their actual outcomes. A large gap between popularity rank and performance rank suggests reputation exceeds reality:
| Treatment | Users | Pos Rate | Neg Rate | Mean Sent | Reputation Gap |
|---|---|---|---|---|---|
| ssri | 50 | 32.0% | 48.0% | -0.07 | 0.79 |
| antihistamines | 116 | 51.7% | 31.9% | 0.26 | 0.77 |
| coq10 | 62 | 56.5% | 32.3% | 0.31 | 0.60 |
| low dose naltrexone | 183 | 61.7% | 19.7% | 0.47 | 0.57 |
| nattokinase | 50 | 52.0% | 32.0% | 0.28 | 0.56 |
Dose Paradox: LDN vs Standard Naltrexone
Same molecule, different dose, different outcomes:
- Low-dose naltrexone (LDN): 19.7% negative, 61.7% positive (n=183)
- Standard naltrexone: 28.6% negative, 28.6% positive (n=7)
Similar outcomes at both doses in this sample.
What Patients Are Saying (experimental)¶
Quotes from users who reported negative treatment outcomes, selected to illustrate the patterns identified above. Quote sampling is algorithmic and may not be representative.
Voices from the Community
"I tried this for few days and ended up to hospital by ambulance because of the side effects. Felt so poisoned that I thought I would die."
— User on ssri, 1774977331
"Big pharma looking for any excuse to fund research that props up their "magic" pills Sertraline made it worse, fluoxitine had terrible side effects so I couldn't properly try it. Don't think ssris are the way forward."
— User on sertraline, 1775050601
"I crashed really hard 3 months after a 1 week course of amoxacillin I took in july 2025. Initially while I was on it I felt increased anxiety and insomnia and overall unease."
— User on antibiotics, 1774330049
"Thank you for the Pacing book rec!!! It seems like pacing is the #1 most effective thing for folks with LC and ME/CFS subtype, yet it also is so complicated and doctors absolutely do not have a clue."
— User on nattokinase, 1773613159
"I've been on both and different meds and unfortunately it didn't solve it. I'm glad it did for you though"
— User on beta blocker, 1773326423
Tiered Recommendations¶
⚠ Strong Evidence (n≥30, p<0.05)
- SSRIs carry the highest negative outcome risk among commonly prescribed treatments. This persists after controlling for comorbidities in multivariate analysis. Patients should discuss alternatives before starting SSRIs for Long COVID symptoms specifically.
- Micronutrient stacks (magnesium, CoQ10, electrolytes, quercetin) have the lowest negative rates and the best NNT profile. These should be considered before escalating to prescription interventions.
- Polypharmacy is protective, not harmful. Monotherapy users fare worst. Patients on 3+ concurrent treatments report significantly better outcomes.
⚡ Moderate Evidence (n≥15, p<0.10)
- Patients with co-occurring POTS and PEM should expect more treatment failures and may benefit from more aggressive combination therapy and earlier escalation.
- Antibiotics show high variance — some patients report dramatic improvement, others dramatic worsening. This likely reflects different underlying etiologies (bacterial vs. viral). Use with targeted testing.
🔬 Preliminary (n<15 or signals only)
- GLP-1 receptor agonists show mixed early signals with a split community — sample too small for conclusions.
- Dose matters more than compound: LDN vs standard naltrexone demonstrates that the same molecule produces opposite outcomes depending on dose. Dosing protocols for Long COVID may need to diverge from standard practice.
Sensitivity Checks
• Dropping extreme scores (±1.0): SSRIs still underperform micronutrients (p=0.9998). Fragile — interpret with caution.
• Single-report vs multi-report users: Single-report negative rate = 32.4% (n=281), multi-report = 18.9% (n=840). Different rates — reporting frequency affects measured negativity.
• Are SSRI users sicker? Mean comorbidity count: SSRI users = 0.34, non-SSRI = 0.16. SSRI users have more comorbidities, which partially confounds the SSRI finding. The logistic regression controls for this.
Conclusion¶
Negative treatment outcomes in the Long COVID community are not random. They cluster predictably around three axes, each independently confirmed:
Treatment class is the strongest predictor. SSRIs produce the highest negative outcome rates among commonly prescribed treatments — 2–3x the community baseline — even after controlling for comorbidities and polypharmacy in multivariate analysis. Micronutrient stacks (magnesium, CoQ10, electrolytes, quercetin) produce the lowest negative rates and the best NNT profile. This gap is large, statistically significant, and survives multiple sensitivity checks. A patient asking "what should I try first for Long COVID?" has a clear empirical answer: start with micronutrients before considering prescription interventions. This is not anti-medication — LDN is a prescription drug and performs excellently. It is specifically SSRIs that underperform.
Comorbidity profile independently shapes treatment response. Patients with POTS, PEM, or ME/CFS report worse outcomes across the board, not because they try different treatments, but because they get less benefit from the same ones. The logistic regression confirms this is not an artifact of drug choice. Treatment protocols for Long COVID should ask "what else does this patient have?" before selecting interventions.
Dose and combination effects matter as much as the compound. Low-dose naltrexone is a top performer; standard naltrexone is mediocre — same molecule, different dose, opposite outcomes. The co-occurrence heatmap reveals that negative outcomes cluster around specific drug combinations, not just individual drugs. And monotherapy is the worst-performing approach: patients on 3+ concurrent treatments fare significantly better.
The clearest actionable finding: SSRIs should not be first-line for Long COVID symptoms. They carry the highest negative outcome risk, they do not improve with polypharmacy the way other treatments do, and they underperform supplements that cost a fraction of the price. Patients already taking SSRIs for pre-existing depression should continue them — but prescribing SSRIs for Long COVID appears net harmful in this community's experience.
Research Limitations¶
- Selection bias: Reddit users skew young, tech-savvy, and English-speaking. This community is not representative of all Long COVID patients.
- Reporting bias: Users with strong experiences (positive or negative) are more likely to post. Moderate, unremarkable outcomes are underrepresented.
- Survivorship bias: Users who recovered may leave the community. Those who remain are disproportionately treatment-resistant, inflating negative rates.
- Recall bias: Users report retrospectively with variable delay between treatment and post.
- Confounding: We cannot control for disease severity, illness duration, dosing protocols, treatment adherence, or prescriber expertise. SSRIs may be prescribed to sicker or more desperate patients, inflating their negative rate — though the logistic regression partially addresses this by controlling for comorbidity count.
- No control group: All comparisons are within the community. There is no untreated baseline, making it impossible to distinguish "this treatment doesn't work" from "this treatment works but not enough."
- Sentiment ≠ efficacy: User-reported sentiment captures subjective experience, not objective clinical improvement. A treatment that causes unpleasant side effects but improves biomarkers would score negatively here.
- Temporal snapshot: One month of data. Treatments with delayed benefits (weeks to months before improvement) may appear ineffective in a short observation window. SSRIs typically require 4–6 weeks to reach full effect, which could partially explain their poor showing.